NasdaqGS - Delayed Quote USD

LAVA Therapeutics N.V. (LVTX)

1.3200

0.0000

(0.00%)

At close: 4:00:00 PM EDT

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 days ago

LVTX
0.00%
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on its proprietary Gammab

GlobeNewswire 7 days ago

LVTX
0.00%
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksd

GlobeNewswire last month

LVTX
0.00%
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and P

GlobeNewswire last month

LVTX
0.00%
LAVA Announces Evaluation of Strategic Options

Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused

GlobeNewswire 2 months ago

LVTX
0.00%
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end 2025 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing

GlobeNewswire 4 months ago

LVTX
0.00%
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266, for hematologic malignancies, and a $5.0 million milestone payment from Johnson and JohnsonCash runway extended into 2027, based on a cash balance of $78.9 million, as of September 30, 2024 UTRECHT, The Neth

GlobeNewswire 5 months ago

LVTX
0.00%
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation DetailsFormat: Fireside ChatDate: Monday, September 9, 2024T

GlobeNewswire 8 months ago

LVTX
0.00%
LAVA Reports Second Quarter 2024 Financial Results and Business Update

Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for LAVA-1207Next data update for LAVA-1207 program expected in Q4 2024Strong balance sheet with cash of $86.8 million supports runway into mid-2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-onc

GlobeNewswire 8 months ago

LVTX
0.00%
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Presentation Details Format: Fireside Chat Date: Tu

GlobeNewswire 10 months ago

LVTX
0.00%
LAVA Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST. All relevant documents and information relating to the annual general meeting, including the notice and agenda for

GlobeNewswire 11 months ago

LVTX
0.00%
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Presentation Details Format: Fireside

GlobeNewswire 11 months ago

LVTX
0.00%

Performance Overview

Return	LVTX	S&P 500 (^GSPC)
YTD	+38.80%	-0.63%
1-Year	-50.19%	+9.83%
3-Year	-61.63%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

LAVA Therapeutics N.V. (LVTX)

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

LAVA Announces Evaluation of Strategic Options

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LAVA Reports Second Quarter 2024 Financial Results and Business Update

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Announces Annual Meeting of Shareholders

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

Performance Overview